BMO Capital analyst Do Kim notes Ionis Pharmaceuticals (NASDAQ: IONS) partner Biogen reported 2Q17 Spinraza sales of $203mn, easily beating ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Biogen (BIIB) PT Raised to $328 at BMO Capital; '2Q17 Couldn’t Have Been Better Operationally'July 26, 2017 10:53 AM Biogen (BIIB) PT Raised to $285 at UBS Following Strong 2Q July 26, 2017 8:44 AM Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on WeaknessJuly 25, 2017 1:51 PM Buy Ionis Pharmaceuticals (IONS) on Growth Concerns Weakness - Needham & CompanyJuly 25, 2017 12:05 PM